Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3-6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:197 |
|---|---|
| Enthalten in: |
British journal of haematology - 197(2022), 6 vom: 04. Juni, Seite 697-708 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Riise, Jon [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.06.2022 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337857016 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337857016 | ||
| 003 | DE-627 | ||
| 005 | 20231225235353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18149 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337857016 | ||
| 035 | |a (NLM)35254660 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Riise, Jon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3-6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD8 T-cell response | |
| 650 | 4 | |a anti-CD20 antibody | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) vaccination | |
| 650 | 4 | |a humoral response | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epitopes | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Meyer, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Blaas, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Adity |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Trung T |e verfasserin |4 aut | |
| 700 | 1 | |a Delic-Sarac, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Hestdalen, Malu Lian |e verfasserin |4 aut | |
| 700 | 1 | |a Brodin, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Rustad, Even Holth |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Ke-Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Vaage, John Torgils |e verfasserin |4 aut | |
| 700 | 1 | |a Nissen-Meyer, Lise Sofie Haug |e verfasserin |4 aut | |
| 700 | 1 | |a Sund, Fredrik |e verfasserin |4 aut | |
| 700 | 1 | |a Wader, Karin F |e verfasserin |4 aut | |
| 700 | 1 | |a Bjornevik, Anne T |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Nygaard, Gro O |e verfasserin |4 aut | |
| 700 | 1 | |a König, Marton |e verfasserin |4 aut | |
| 700 | 1 | |a Smeland, Sigbjørn |e verfasserin |4 aut | |
| 700 | 1 | |a Lund-Johansen, Fridtjof |e verfasserin |4 aut | |
| 700 | 1 | |a Olweus, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Kolstad, Arne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 197(2022), 6 vom: 04. Juni, Seite 697-708 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:197 |g year:2022 |g number:6 |g day:04 |g month:06 |g pages:697-708 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18149 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 197 |j 2022 |e 6 |b 04 |c 06 |h 697-708 | ||